Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH

/PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib...

Related Keywords

Guangzhou ,Guangdong ,China ,Georgia ,United States ,Shanghai ,Hong Kong ,New Jersey ,Atlanta ,Boston ,Massachusetts ,Beijing ,Nanjing ,Jiangsu ,American ,Wei Xu ,Daobin Zhou ,Orelabrutinib Monotherapy ,Jianyong Li ,Ming Hou ,Waldenstrom Macroglobulinemia ,Innocare Pharma ,Chunhua Lu ,American Society Of Hematology ,China National Medical Products Administration ,Drug Administration ,American Society ,Annual Meeting ,Professor Daobin Zhou ,Chronic Lymphocytic ,Small Cell Leukemia ,Primary Immune Thrombocytopenia ,Professor Ming Hou ,Refractory Waldenstrom ,Refractory Chronic Lymphocytic ,Small Lymphocytic Lymphoma ,Updated Long Term Results ,Selective Bruton ,Tyrosine Kinase ,Chronic Lymphocytic Leukemia ,Mantle Cell Lymphoma ,Marginal Zone Lymphoma ,Central Nervous System Lymphoma ,Breakthrough Therapy Designation ,Multiple Sclerosis ,Systemic Lupus Erythematosus ,Innocare ,Biotechnology ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Trade Show News ,Surveys ,Olls And Research ,New Products Amp Services ,